Detailed Narrative
Operational Efficiency Hits Record Highs
MRPL achieved its best-ever energy efficiency performance in Q3 FY26, posting an MBN of 67. This operational excellence was complemented by a fuel and loss (F&L) figure of 10.06%. Management expects F&L to improve further to between 9.5% and 10% in the next fiscal year following the completion of the grid power project, which will reduce internal fuel consumption for power generation.
Aggressive Pivot to Retail Marketing
The company is shifting its strategy from being a 'base refinery' to a full-fledged marketing entity. With 200 outlets currently, MRPL aims to reach 250 by March 2026, 500 in three years, and 1,000 in five years. Management believes retail margins are superior to refinery transfer prices and provide stability against volatile export markets, which currently account for 40% of production.
Crude Sourcing and Sanctions Navigation
Management confirmed that MRPL is in strict compliance with international sanctions and is currently not importing any Russian crude. Approximately 40% of crude is sourced from the Middle East, primarily through term contracts with Saudi Aramco. The refinery's complexity allows it to process heavy crudes (15-16 API) like Merey or Maya, which currently make up 70-72% of the crude slate for the first nine months of the year.
Capital Expenditure and Debt Management
MRPL has committed to an annual capex of approximately ₹1,500 crores for both FY26 and FY27. Of this, roughly ₹400-450 crores is earmarked for growth projects like retail expansion and grid power, while the remainder is for maintenance and revamping. The company successfully pushed debt below ₹10,000 crores to ₹9,290 crores, with a significant portion of long-term debt (₹4,500 crores in NCDs) locked in until 2028.
Future Growth in Bio-ATF and Specialty Chemicals
MRPL is positioning itself for the energy transition by establishing India's first Bio-ATF plant at a cost of ₹364 crores. This will enable compliance with CORSIA norms and allow for 1% blended ATF supply starting in 2027. Additionally, the company is running a pilot plant for Isobutyl Benzene (IBB), a pharmaceutical base, marking a strategic entry into high-margin specialty chemicals.